Skeletal muscle mass predicts the outcome of nivolumab treatment for non-small cell lung cancer
In conclusion, SM loss may be a predictive factor of poor outcomes in NSCLS patients undergoing nivolumab therapy.
Source: Medicine - Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | CT Scan | Internal Medicine | Lung Cancer | Non-Small Cell Lung Cancer | Study | Women